论文部分内容阅读
目的:探讨药物性肝损伤的临床关联性及特点。方法:对2008-2012年我院112例药物性肝损伤患者临床资料进行回顾性分析,内容包括损伤类型、用药至发生肝损伤间隔时间、停药后至体内肝脏生化指标下降50%所需时间、各类型药物性肝损伤患者体内生化指标对比情况等,给予统计学分析,得出结论。结果:112例药物性肝损伤患者大部分均为肝细胞型肝损伤,所占比例为54.46%;药物性肝损伤患者临床类型不同,其体内各项生化指标表现情况也有所不同;肝细胞型肝损伤患者用药至发生肝损伤间隔时间最长,而胆汁淤积型肝损伤患者停药后至体内肝脏生化指标下降50%所需时间最长,对比结果具有统计学意义(P<0.05)。结论:临床医师应根据肝损伤患者近期用药情况判断其是否发生药物性肝损伤,并结合其临床实际表现及生化检验结果确定肝损伤类型,制定具有针对性的治疗方案。
Objective: To investigate the clinical relevance and characteristics of drug-induced liver injury. Methods: The clinical data of 112 patients with drug-induced liver injury in our hospital from 2008 to 2012 were analyzed retrospectively, including the type of injury, interval from the administration of drug to occurrence of liver injury, the time required to reduce the biochemical index of liver in vivo by 50% , Various types of drug-induced liver injury in patients with biochemical indicators of contrast, give statistical analysis, draw conclusions. Results: Most of the 112 cases of drug-induced liver injury were hepatocellular liver injury, accounting for 54.46%. The clinical types of patients with drug-induced liver injury were different, and their biochemical indicators were different. Patients with liver injury had the longest interval between medication and occurrence of liver injury, while longest time was required to reduce the biochemical indicators of liver in patients with cholestatic liver injury by 50% after stopping drug administration. The results were statistically significant (P <0.05). Conclusion: Clinicians should determine whether drug-induced liver injury occurs according to the recent medication of patients with liver injury and determine the type of liver injury according to their clinical manifestations and biochemical test results and formulate targeted treatment plans.